02 February 2022 Irma Thomas gets animated about the importance of clinical trials

The Soul Queen of New Orleans, Irma Thomas, is spreading the word about clinical trials in a new animated short co-produced by a Tulane University community engaged research initiative.

27 January 2022 Educational Animation features Irma Thomas, Soul Queen of New Orleans

Addressing misinformation about COVID-19 and clinical studies is an ongoing process for both The Louisiana Community Engagement Alliance against COVID-19 Disparities (LA-CEAL), a state-wide consortium of community and academic institutions, and NoiseFilter, a health education podcast and animation series.

05 January 2022 The COVID-19 Treatment Guidelines Panel's Statement on Anticoagulation in Hospitalized Patients With COVID-19

COVID-19 has been associated with inflammation and a prothrombotic state accompanied by increases in fibrinogen and D-dimer...

23 December 2021 Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19.

20 December 2021 ASH Guidelines on Use of Anticoagulation in Patients with COVID-19

ASH has issued recommendations for the use of anticoagulation in critically and acutely ill patients for which the evidence will be re-evaluated in a continual fashion. This webpage will be updated as the evidence for recommendations are evaluated.

07 December 2021 WHO recommends against the use of convalescent plasma to treat COVID-19

WHO has updated its living guideline on COVID-19 therapeutics to include convalescent plasma. For non-severe COVID-19 patients, WHO recommends against its use, while it should only be used within clinical trials for severe and critical COVID-19 patients.

06 December 2021 Penn Nursing leads initiative to address COVID-19 disparities in Philadelphia

Penn's School of Nursing is leading the Philadelphia Community Engagement Alliance Against COVID-19 Disparities to address the substantial health disparities in the city.

19 November 2021 Alabama CEAL study finds evidence of vaccine hesitation due to mistrust

Researchers with the Alabama Community Engagement Alliance (CEAL) Against COVID-19 Disparities, which is part of the National Institutes of Health’s CEAL, recently published findings from a study focused on understanding vaccine hesitancy among African American and Latinx communities.

18 November 2021 Early Convalescent Plasma for High-Risk Outpatients with Covid-19

Early administration of convalescent plasma obtained from blood donors who have recovered from coronavirus disease 2019 (Covid-19) may prevent disease progression in acutely ill, high-risk patients with Covid-19.

16 November 2021 No Benefit of Antiplatelets in Noncritical COVID: ACTIV-4a

Giving the P2Y12 inhibitor antiplatelet drugs ticagrelor or clopidogrel to noncritically ill, hospitalized patients with COVID-19 did not result in a greater number of days alive and free of cardiovascular or respiratory organ support in the ACTIV-4a trial.

12 November 2021 The ACTIV COVID-19 Clinical Trials: 5 Things to Know

The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative is currently conducting clinical trials to advance COVID-19 vaccines and therapeutics to both prevent COVID-19 and treat mild to life-threatening COVID-19 infection.

21 October 2021 Cardiopulmonary events not reduced in symptomatic outpatients with COVID-19

Cardiopulmonary events were unaffected by antithrombotic therapy in symptomatic outpatients with COVID-19 but the trial was terminated early.

19 October 2021 New study demonstrates community engagement efforts are critical to ensuring the equitable inclusion of BIPOC communities in vaccine clinical trials

A team of research experts from the COVID-19 Prevention Network (CoVPN), headquartered at Fred Hutchinson Cancer Research Center, has demonstrated that through robust community engagement, equitable inclusion in vaccine clinical trials can make a powerful impact in the health of underrepresented communities.

13 October 2021 ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

The lack of benefit with aspirin or apixaban “is what we would call a very informative neutral result,” Paul Ridker says.

11 October 2021 Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

Among symptomatic but clinically stable outpatients with COVID-19, does adding antithrombotic therapy, compared with placebo, reduce major cardiopulmonary adverse outcomes over a 45-day treatment period?

07 October 2021 Anticoagulant Therapy in Patients Hospitalized With COVID-19

Since the early days of the COVID-19 pandemic, clinicians have reported altered coagulation in hospitalized patients, with both thrombotic as well as hemorrhagic events.

30 September 2021 ‘It’s Our Turn’ COVID-19 Art Contest for Youth and Young Adults Offers $250 Prize For 12 Winners

With their passion and creativity, many individuals have found ways to add their unique spin on public service messages, especially regarding COVID-19 mask wearing or vaccination brochures or videos.

21 September 2021 Dynamic duo forms a research connection

Maria Jose Baeza Robba, second-year Ph.D. student, and Nicholas Metheny, assistant professor, joined forces to tackle grad school, research firsts, and COVID-19 concerns in the sexual and gender minority community.

10 September 2021 In hard-hit neighborhoods, Philly CEAL outreach aims to address COVID disparities

Through community engagement and improved information dissemination, researchers at Penn Nursing, Penn Medicine, and Annenberg, in conjunction with the City of Philadelphia, are working to increase vaccination and testing rates and decrease new COVID-19 infections.

01 September 2021 ACTIV-3: AZ Covid-19 antibody cocktail trial set to complete enrolment by end of month

A large study evaluating AstraZeneca’s Covid-19 monoclonal antibody will soon have data on its use in hospitalised patients.

28 August 2021 Please Reevaluate the Data on Convalescent Plasma for COVID-19

Early administration of convalescent plasma with high antibodies may offer hope to some patients

20 August 2021 Low vaccination rates persist in Detroit households with children

With a new school year three weeks away and cases of COVID-19 on the rise again, vaccination rates in the households of school-age children will play an important role in how school districts weigh their options for returning to the classroom.

20 August 2021 Get stuck with Chuck. UAB MHRC and Charles Barkley host COVID-19 vaccine rally

The Leeds, Ala., and NBA basketball legend brings his plea for widespread vaccination against COVID-19 to a vaccine rally on Saturday, Aug. 28.

18 August 2021 NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms

The final results of the Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) demonstrate that COVID-19 convalescent plasma did not prevent disease progression in a high-risk group of outpatients with COVID-19, when administered within the first week of their symptoms.

18 August 2021 Publication: NHLBI C3PO Trial Results

Early administration of convalescent plasma obtained from blood donors who have recovered from coronavirus disease 2019 (Covid-19) may prevent disease progression in acutely ill, high-risk patients with Covid-19.

08 August 2021 Anticoagulants can increase survival in hospitalised patients with moderate COVID-19, trial data show

Anticoagulation with heparin could increase survival and reduce the need for organ support in patients hospitalised with moderate COVID-19, compared with usual care, results from three trials have shown.

06 August 2021 Christus Trinity Mother Frances researches life-saving devices, procedures

Christus Trinity Mother Frances is researching never-before-seen life-saving projects that have the potential to change the medical field, all in Tyler.

06 August 2021 Full dose anticoagulation with heparin improves outcomes for moderately ill COVID-19 patients

Collaborative international clinical trials testing full dose anticoagulation with heparin (a blood thinner) in both moderately ill and critically ill patients has found the treatment improves outcomes and reduces the need for vital organ support such as mechanical ventilation in moderately ill patients.

04 August 2021 Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19).

04 August 2021 Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.

04 August 2021 Full-dose blood thinners reduce the need for organ support in moderately ill COVID-19 patients, but not in critically ill patients

A large clinical trial conducted worldwide shows that treating moderately ill hospitalized COVID-19 patients with a full-dose blood thinner reduced their need for organ support, such as mechanical ventilation, and improved their chances of leaving the hospital.

22 July 2021 Safety concern is main reason many Detroiters skip vaccination

About half of adults living in Detroit are not yet fully vaccinated against COVID-19, according to data just released from a University of Michigan survey.

22 July 2021 Clinical and Virological Response to a Neutralizing Monoclonal Antibody for Hospitalized Patients with COVID-19

Bamlanivimab, a neutralizing monoclonal antibody given in combination with remdesivir, did not improve outcomes among hospitalized COVID-19 patients based on an early futility assessment.

09 July 2021 Heparin for Moderately Ill Patients with Covid-19

Heparin, in addition to its anticoagulant properties, has anti-inflammatory and potential anti-viral effects, and may improve endothelial function in patients with Covid-19.

07 July 2021 Racial disparities in COVID-19 vaccination rates persist as delta variant gains steam

Even as the U.S. approaches a coronavirus vaccination rate of 70 percent, racial disparities in who has gotten vaccinated persist, raising questions about how the communities of color that were hit hardest by the first wave of the pandemic will fare against the rapidly spreading delta variant.

30 June 2021 USM Professor Leads Project to Train Community Health Advisors on COVID-19 Awareness in Underserved Areas

Dr. Susan Mayfield Johnson, associate professor in the School of Health Professions at The University of Southern Mississippi (USM), realizes better than most the importance of training community health advisors (CHAs) in underserved areas of Mississippi.

29 June 2021 Rigel Pharmaceuticals (RIGL) Announces ACTIV-4 Host Tissue Study Will Evaluate Fostamatinib In Patents With COVID-19

Rigel Pharmaceuticals (RIGL) today announced that fostamatinib, a novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health (NIH) trial in hospitalized patients with COVID-19.

28 June 2021 NIH extends CEAL Grant to promote COVID-19 vaccines

In the fall of 2020, Alabama was one of 11 states invited to be part of the National Institutes of Health’s Community Engagement Alliance Against COVID-19 Disparities.

26 June 2021 Trevena Enrolls First Patient For ACTIV-4 Host Tissue Study Of Its Covid Drug

Trevena, Inc. (TRVN) on Monday said first patient has been enrolled in the ACTIV-4 Host Tissue study of the company's investigational drug TRV027, for the treatment of Covid-19.

25 June 2021 Health disparities and the racial burden of COVID-19

With new evidence suggesting Black and Hispanic populations were disproportionately affected by the pandemic, experts weigh in on the importance of vaccination and addressing health disparities

21 June 2021 ACTIV4a moderate state COVID-19 study arm stopped

Enrollment and study prescribed treatment of patients who meet the criteria for the moderate state (non-ICU level of care) in the ACTIV4a study has been stopped due to meeting the predetermined criteria of futility for adding the P2Y12 inhibitor to standard of care.

21 June 2021 NIH ACTIV-4B COVID-19 outpatient thrombosis prevention trial ends early

A year ago, investigators set out to study whether symptomatic COVID-19 outpatients should be given anticoagulant or antiplatelet therapy to prevent clots that were reported among some patients with COVID-19.

15 June 2021 Penn Nursing-Led Philly Team: $1.4 Million NIH Grant to Expand COVID-19 Outreach

José A. Bauermeister and Antonia M. Villarruel are leading one of 10 research teams from across the country that received National Institutes of Health (NIH) grants totaling $14 million to extend the reach of the NIH’s Community Engagement Alliance (CEAL) Against COVID-19 Disparities.

14 June 2021 UAMS Project Part of National Effort to Reduce COVID-19 in Hardest Hit Populations

LITTLE ROCK — UAMS researchers and their community partners across Arkansas are studying the causes behind COVID-19’s devastating impact on minorities and developing plans to help increase vaccination rates.

25 May 2021 UIC leads multi-center collaborative to help communities affected by COVID-19

The University of Illinois Chicago has been selected by the National Institutes of Health as the principal site of a multi-center collaborative in the Chicago area that will bolster research and outreach to help communities disproportionately affected by COVID-19.

20 May 2021 Philly CEAL team receives NIH grant to extend COVID-19 outreach

José A. Bauermeister, PhD, and Antonia M. Villarruel, PhD, are leading one of 10 new research teams from across the country that received National Institutes of Health (NIH) grants totaling $14 million to extend the reach of the NIH's Community Engagement Alliance (CEAL) Against COVID-19 Disparities.

13 May 2021 MD, U.S. Vaccine Initiatives to Help Youths, Communities of Color

As President Joe Biden met on Tuesday with governors to announce new vaccination efforts, a federal agency unveiled funding to boost outreach for vaccine research in Maryland’s communities of color.

13 May 2021 Washington U. gets $1.9 million to boost vaccination rates among Black residents in St. Louis and St. Louis County

After getting their COVID-19 vaccine, Black residents will be given “golden tickets” to hand out to their unvaccinated friends and family that entitles the ticket holder to personal assistance in scheduling a dose for themselves.

13 May 2021 Kreuter receives $1.9 million in grants to increase vaccinations in St. Louis

Matthew Kreuter, the Kahn Family Professor of Public Health at the Brown School at Washington University in St. Louis, has received a one-year $1.4 million grant from National Institutes of Health’s Community Engagement Alliance (CEAL) Against COVID-19 Disparities.

07 May 2021 VUMC to lead national study to treat severe COVID complications

The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.

04 May 2021 NIH’s ACTIV-4 enrolls 400 hospitalised COVID-19 patients to explore antiplatelet addition to antithrombotic drugs, investigator says

The NIH's ACTIV-4 trial has enrolled 400 patients to evaluate the addition of an antiplatelet to antithrombotics in moderately ill hospitalized COVID-19 patients.

29 April 2021 NIH to invest $29 million to address COVID-19 disparities

To bolster research to help communities disproportionately affected by COVID-19, the National Institutes of Health is funding $29 million in additional grants for the NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities.

29 April 2021 Intermountain Healthcare researchers leading study of treatments for severe COVID-19 patients

Researchers at Intermountain Healthcare are at the forefront of a new, multi-center National Institutes of Health study that is being launched across the nation to test the safety and efficacy of therapeutics for COVID-19 patients with life-threatening cases of the virus, including those with acute respiratory failure.

28 April 2021 How hospitals worldwide are trying to find ways to treat ‘sickest of the sick’ COVID-19 patients

Stumped in finding a way to treat a “devastating” syndrome brought on by COVID-19, doctors and hospitals worldwide are joining a new effort to combat the deadliest damage caused by the novel coronavirus.

22 April 2021 Clinical Trial of Therapeutics for Severely Ill Hospitalized COVID-19 Patients Begins

A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.

21 April 2021 Project focusing on combatting COVID-19 health disparities awarded $1.4 million by NIH

Michigan Community Engagement Alliance — a partnership of researchers and community leaders focused on fighting COVID-19 among low-income and communities of color in Wayne, Genesee, Kent and Washtenaw Counties — was recently awarded $1.4 million by the National Institutes of Health for a grant to be used against COVID-19 disparities.

20 April 2021 Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19

Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiological features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses, and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and patients critically ill with COVID-19. This paper provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.

15 April 2021 Participants Needed for COVID-19 Impact Study by USM, Tougaloo Researchers

The University of Southern Mississippi (USM) and Tougaloo College have partnered to research and better understand the challenges faced by young adults in Mississippi throughout the COVID-19 pandemic, and the group is seeking 18 to 29-year-old individuals across the state to participate in the study.

14 April 2021 UNC Joins Post-Hospital Thrombosis Prevention Study for Covid Patients

UNC is now a fully active clinical site for the ACTIV-4c Post-Hospital Thrombosis Prevention Study.

06 April 2021 New clinical milestones reached as multiple COVID-19 vaccines and therapies advance

Plans for a late-stage test of Valneva SE's COVID-19 vaccine candidate, clinical progress on a different vaccine from Novavax Inc. and advancement for two midstage therapies targeting the virus made clear April 6 that industry efforts to battle the pandemic remain in high gear.

01 April 2021 38% of Detroit residents ‘very likely’ to get COVID-19 vaccine, University of Michigan survey finds

More Detroit residents are “very likely” to get the COVID-19 vaccine compared to last fall, a University of Michigan survey found.

31 March 2021 U-M Receives $1.4M in NIH Funding to expand COVID-19 outreach

Being deeply rooted in the wellbeing of Michigan communities meant that the Community Engagement program at the Michigan Institute for Clinical & Health Research, Michigan Medicine, and the U-M School of Public Health were on the frontlines when the pandemic hit the nation.

31 March 2021 One year of rapid acceleration of diagnostics, and anticipating new challenges

Over the past year, our team of NIH leaders has used this blog to report on an initiative called Rapid Acceleration of Diagnostics – or RADxSM for short.

24 March 2021 Long-Acting Antibody Therapy, AZD7442, for COVID-19 Begins Clinical Trial

AZD7442, an investigational long-acting antibody combination, is being evaluated in an international randomized, controlled Phase 3 clinical trial as part of the National Institutes of Health Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol.

22 March 2021 Vaccine recipients encourage Black community to vaccinate

Across the nation, COVID-19 has taken the lives of African Americans at a disproportionate rate, compared to white Americans.

21 March 2021 Convalescent plasma hype has faded but some say the Covid therapy still holds promise

The most promising use of the blood plasma treatment might come from “super donors,” people who were infected with Covid-19 and then vaccinated.

18 March 2021 Conquering COVID-19 Disparities Among Communities of Color

A federal NIH grant supports work to promote COVID-19 research and inclusivity among African Americans and Hispanics/Latino populations.

12 March 2021 Therapeutic Anticoagulation in Critically Ill Patients with Covid-19 – Preliminary Report

Background Thrombosis may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic anticoagulation would improve outcomes in critically ill patients with Covid-19.

11 March 2021 Listening is key to addressing senior living staff vaccine hesitancy: NIH senior adviser

Combatting vaccine hesitancy in senior living staff members is as easy as listening, according to a senior adviser in the National Institutes of Health.

10 March 2021 Convalescent Plasma Strikes Out As COVID-19 Treatment

More than half a million Americans have received an experimental treatment for COVID-19 called convalescent plasma. But a year into the pandemic, it's not clear who, if anyone, benefits from it.

09 March 2021 NIH launches last trial of anticoagulant treatments for Covid-19

The US National Institutes of Health (NIH) has initiated the last of three Phase III clinical trials of blood thinners (anticoagulant) to prevent life-threatening blood clots in adults with Covid-19.

07 March 2021 Local Leaders Build COVID Vaccine Trust in Black and Latinx Communities

When Rev. Mark-Anthony Middleton looks into the eyes of some of his elderly Black parishioners, he sees a deep, historic hurt that leads them to question the coronavirus vaccine.

04 March 2021 NIH-Sponsored ACTIV-3 Clinical Trial Closes Enrollment into Two Sub-Studies

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrollment in two sub-studies: one examining the investigational monoclonal antibody therapy VIR-7831, and another evaluating the investigational combination monoclonal antibody therapy containing BRII-196 and BRII-198. The sub-studies were halted by the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, on March 1, 2021, following an interim review and recommendation from the independent Data and Safety Monitoring Board (DSMB).

03 March 2021 Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today provided an update on the VIR-7831 (GSK4182136) arm of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial.

02 March 2021 NIH halts trial of COVID-19 convalescent plasma in emergency department patients with mild symptoms

The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in treating emergency department patients who developed mild to moderate symptoms of COVID-19, the disease caused by the coronavirus SARS-CoV-2.

24 February 2021 UCHealth Researchers Studying If Convalescent Plasma Can Keep High-Risk COVID Patients Out Of The Hospital

Researchers at UCHealth University of Colorado Hospital are looking at the effectiveness of convalescent plasma in keeping high-risk COVID-19 patients out of the hospital. They are trying to see if giving a patient, who shows up in the emergency department, the antibody-rich plasma will keep that person from being admitted.

17 February 2021 Virtual town hall Friday on vaccine hesitancy among marginalized communities

Black Alabamians and other marginalized groups are being vaccinated for COVID-19 in much fewer numbers than white Alabamians, and to help address vaccine hesitancy in minority communities, leaders from Tuskegee University and the University of Alabama at Birmingham School of Medicine will hold a virtual town hall on Friday.

16 February 2021 ASU part of state consortium that aims to reduce misinformation about COVID-19 in communities of color

Researchers at Arizona State University's Southwest Interdisciplinary Research Center, along with colleagues at Arizona’s two other state universities and Mayo Clinic, are working to reduce misinformation and mistrust about the COVID-19 pandemic among people disproportionately affected by it.

12 February 2021 Community Health Workers, Often Overlooked, Bring Trust to the Pandemic Fight

Public health authorities are relying on community health workers to be a bridge to communities that have been hardest hit by COVID-19.

10 February 2021 NAACP information sessions to provide health info to underserved communities

The Alabama Branch of the NAACP is hosting a series of free, online information sessions regarding COVID-19 vaccinations.

10 February 2021 International Phase III Trial of Long-Acting Antibodies for COVID-19 Launched

A National Institutes of Health Phase III trial of a long-acting antibody combination therapy developed by AstraZeneca for treating severe COVID-19 is now recruiting patients.

08 February 2021 Clinical trial in hospitalized COVID-19 patients evaluates long-acting antibody therapy

An international randomized, controlled Phase 3 clinical trial has begun evaluating the safety and efficacy of an investigational long-acting antibody combination for treating people hospitalized with COVID-19.

05 February 2021 NIH’s ACTIV-3 Covid-19 trial plans to add another mAb in few weeks; futility analysis GSK/Vir’s and Brii’s mAbs expected in February, sources say

The National Institutes of Health’s (NIH’s) Phase III ACTIV-3 trial will add another monoclonal antibody (mAb) therapy to its Covid-19 treatment platform in the next few weeks, said a source familiar with the study and a trial investigator.

04 February 2021 Alabama’s NAACP hosting information sessions to answer questions related to the COVID-19 vaccine

The Alabama NAACP will host a series of four info sessions to address questions and concerns related to the COVID-19 vaccine, according to a release from the organization.

02 February 2021 Can Blood Thinners Keep Certain COVID-19 Patients Out of the ICU?

COVID-19 patients receiving a full intravenous dose of heparin were less likely to need organ support

29 January 2021 UH Moment: Addressing Concerns About COVID-19 Vaccines

With many Americans skeptical about the safety and effectiveness of new vaccines, the University of Houston is working to understand why people are hesitant to be vaccinated and how to change their perceptions.

29 January 2021 Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients: Interim Analysis Results

Results of the interim analysis for a large clinical trial conducted worldwide with full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19.

28 January 2021 Pandemic spurs quest to enroll more Black Americans in vaccine trials

Infectious disease doctor Angela Branche needed help.

27 January 2021 Florida doctors push to make COVID-19 vaccine education accessible in minority communities

Minorities have been disproportionately affected by COVID-19, with more infections and deaths than any other group.

25 January 2021 NIH reports full-dose blood thinners improve Covid-19 outcome

The National Institutes of Health (NIH) has reported data from a large clinical trial, which showed that full-dose anticoagulation (blood thinners) lowered the need for vital organ support in moderately-ill, hospitalised Covid-19 patients.

22 January 2021 Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients

In large clinical trial conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support—such as the need for ventilation.

22 January 2021 Pitt-Led NIH Trial Platform Shows Blood Thinners Decrease Need for Life Support in COVID-19 Patients

A worldwide set of clinical trials coordinated in part by researchers at the University of Pittsburgh has found that giving full dose anti-coagulation treatments, or blood thinners, to moderately ill patients hospitalized for COVID-19 reduced the need for vital organ support, such as ventilation. The researchers say that adopting the cheap, readily available treatment could help reduce the burden on intensive care units.

20 January 2021 UH researchers address COVID-19 vaccine hesitancy in minority communities

Many Americans, particularly minorities, are hesitant or skeptical about receiving the COVID-19 vaccine, and institutions, like the University of Houston, are hoping to change that.

16 January 2021 Tallahassee Memorial HealthCare participating in blood thinner study as COVID treatment

A research team at Tallahassee Memorial HealthCare has joined a national study to see if blood thinners can help prevent life-threatening blood clots from forming in the bloodstreams of people who have tested positive for COVID-19 and who do not require hospitalization.

15 January 2021 Lakeland Regional Health leads the state in COVID-19 blood clot research

LAKELAND, Fla. — Lakeland Regional Health is doing ground-breaking research that is answering crucial questions to help prevent complications from COVID-19.

14 January 2021 Tennessee vaccine shortage as doctors warn of new, aggressive virus strain

The Morehouse College School of Medicine has just released a new public service announcement urging people, particularly people of color, to get the COVID-19 vaccine “for you, for me, for all of us.”

13 January 2021 New Morehouse PSA urges vaccinations ‘for all of us’

11 January 2021 Tallahassee Memorial HealthCare researchers looking at blood thinners as possible COVID-19 treatment

TALLAHASSEE, Fla. (WCTV) - Tallahassee Memorial HealthCare says one of its research teams has joined a national study to evaluate blood thinners as a possible treatment for COVID-19 in patients who do not need to be hospitalized.

06 January 2021 NIH initiates trial of antibody combination therapy in Covid-19 patients

The National Institutes of Health (NIH) in the US has announced the initiation of a Phase II/III clinical trial of a combination investigational monoclonal antibody therapy for treating individuals with mild-to-moderate Covid-19.

05 January 2021 (BPRW) National Institutes of Health: The Power of Trust and Truth

Getting and sharing the facts about COVID-19, trusting science can help turn the tide for pandemic-strapped communities of color

28 December 2020 COVID Clot Prevention Evidence Beginning to Bud

Clotting problems with severe COVID-19 became clear in the early days of the pandemic; now at around the 1-year mark of the first cases, research is just beginning to reveal what prophylactic strategies are best.

24 December 2020 Statement from the REMAP-CAP trial: International Trials of Blood Thinners Pause Enrollment of Critically Ill COVID-19 Patients

Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrolment for one group of patients.

23 December 2020 Mistrust of government is significant roadblock to Black American vaccination efforts

The rollout of the first approved COVID-19 vaccine this week is raising questions of when the game-changing inoculations will be ready for everyday Americans.

23 December 2020 NIH Sponsored ACTIV-3 Trial Results Published

Recent data from a Phase 3, randomized, placebo-controlled clinical trial that tested the investigative monoclonal antibody LY-CoV555 in hospitalized patients with the coronavirus disease 2019 (COVID-19), showed preliminary results that it did not provide any clinical benefit in comparison to a placebo.

23 December 2020 Lilly’s monoclonal antibody fails in NIH-sponsored ACTIV-3 trial

The US National Institutes of Health (NIH) has announced that preliminary results from a Phase III clinical trial of Eli Lilly and Company’s investigational monoclonal antibody, LY-CoV555, showed it failed to provide clinical benefit in hospitalised Covid-19 patients.

23 December 2020 Results of NIH-sponsored ACTIV-3 trial published

Preliminary results of Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published in The New England Journal of Medicine.

22 December 2020 NIH ACTIV Trial of blood thinners pauses enrollment of critically ill COVID-19 patients

Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, therapeutic anticoagulation drugs did not reduce the need for organ support. Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.

22 December 2020 Results of NIH-sponsored ACTIV-3 trial published

Preliminary results of a Phase 3, randomized, placebo-controlled clinical trial testing the investigative monoclonal antibody LY-CoV555 in hospitalized COVID-19 patients were published today in The New England Journal of Medicine.

22 December 2020 A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients who are hospitalized with Covid-19.

21 December 2020 Some Black MS residents are skeptical of COVID vaccine. Can researchers change minds?

A few days ago, Vanessa Reed got a letter in the mail. A company called ClinicalResearch.com wanted her to know she could get up to $740 and potentially a free COVID-19 vaccine if she signed up for a clinical trial.

20 December 2020 Mistrust, disinformation among Latinos on Covid vaccine worries Hispanic doctors

MIAMI — As vaccinations against the coronavirus begin to roll out across the country, Dr. Olveen Carrasquillo says he's been getting many questions from his predominantly Latino patients, including whether the vaccine contains the virus and whether there are side effects to taking it.

17 December 2020 Investigational COVID-19 therapeutics to be evaluated in large clinical trials

Two randomized, controlled Phase 3 clinical trials have begun evaluating investigational monoclonal antibodies for their safety and efficacy in treating people hospitalized with moderate COVID-19.

10 December 2020 New nationwide collaborative study to determine factors that predict disease severity and long-term health impacts of COVID-19

A new nationwide study of more than 50,000 individuals is underway to determine factors that predict disease severity and long-term health impacts of COVID-19.

07 December 2020 Tulane receives $1 million NIH grant to engage communities hardest hit by COVID-19

The National Institutes of Health has awarded a $1 million grant to Tulane University to launch an outreach initiative to reach ethnic and racial minority communities in Louisiana that are disproportionately affected by the COVID-19 pandemic.

03 December 2020 Intermountain Healthcare Researchers launch New Study to determine whether Blood Thinners prevent clots, Illness severity in patients with COVID-19

Salt Lake City, Utah – As part of a national movement to develop treatments and therapies for COVID-19, Intermountain Healthcare researchers are launching a study in Utah to examine the effects of anticoagulants on patients who have tested positive for the novel coronavirus.

28 November 2020 The power of trust and truth sharing facts about COVID-19 Science can turn tide for communities of color

COVID-19 has killed more than 230,000 people in the U.S., and the death toll continues to rise at a rate of about 1,000 per day. We know, however, that families and communities don’t count their losses in thousands or hundreds; they count them one-by-one – a father, a teacher, a sister, a friend, a nurse, a son, a Tribal elder, a church member. And these losses hurt.

28 November 2020 WSU partners with Johns Hopkins to conduct COVID-19 plasma trials

Researchers at Wayne State University are studying the potential benefits of using convalescent blood plasma from COVID-19-infected donors on exposed and diagnosed patients, to see if antibodies can help fight SARS-CoV-2, the novel coronavirus which causes COVID-19.

19 November 2020 Knocking down the COVID-19 disparities through university community partnerships

The University of Arizona, in partnership with Arizona State University, Northern Arizona University and the Mayo Clinic in Scottsdale, made Arizona one of the 11 states that are participating in the National Institute of Health’s Community Engagement Alliance Against COVID-19 Disparities.

18 November 2020 Florida Universities and Health Centers Partner on COVID-19 Community Engagement, Research

Armed with a $1 million award from the National Institutes of Health (NIH), Universities and health care entities throughout the state of Florida are collaborating to provide outreach and engagement to ethnic and racial minority communities disproportionately affected by the COVID-19 pandemic.

16 November 2020 Study of COVID-19 Risk and Long-Term Effects Underway at 37 U.S. Academic Medical Centers

A new nationwide study of more than 50,000 individuals is now underway to determine factors that predict disease severity and long-term health impacts of COVID-19.

16 November 2020 Bond Community Health Center enrolls Florida patients in national COVID-19 study

Bond Community Health Center in Tallahassee is the first site in Florida to enroll patients in a national study to see if blood thinners can help prevent life-threatening blood clots from forming in people who have tested positive for COVID-19.

12 November 2020 Amid Pandemic, American Lung Associate Expands Awards and Grants Research Investment on COVID-19, Lung Diseases

CHICAGO, Nov. 12, 2020 /PRNewswire/ -- The American Lung Association has expanded its awards and grants program through its COVID-19 Action Initiative to include 12 new COVID-19 research awards, and today announced an investment of approximately $11.55 million in promising research to fund an expected 98 awards for 2021.

10 November 2020 Lilly’s monoclonal antibody is the first to be authorized for use in treating COVID-19

Lilly's monoclonal antibody therapy, bamlanivimab (LY-CoV555), has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for the treatment of adults and children with recently diagnosed, mild to moderate COVID-19.

03 November 2020 Physician-Scientist Leads Program to Tackle COVID-19 Health Disparities in Arizona

Dr. Sairam Parthasarathy is one of 11 principal investigators for the National Institutes of Health Community Engagement Alliance Against COVID-19 Disparities.

30 October 2020 AZ Orgs Prepare to Target Health Disparities, Community Health

University of Arizona Health Sciences will spearhead efforts to bolster community health outreach and engagement in light of COVID-19 disparities.

22 October 2020 Arterial wall cells offer insight into coronavirus’ rampage from head to toe

Peter Libby, M.D., never imagined nearly 40 years ago that his research would contribute to the current understanding of how the novel coronavirus targets and ravages the blood vessels in people with COVID-19.

20 October 2020 Morehouse School of Medicine awarded $1 Million NIH grant for COVID-19 community engagement research, health communications

Morehouse School of Medicine received a $1 million award from the National Institutes of Health for COVID-19 pandemic outreach and engagement efforts in ethnic and racial minority communities. Morehouse will form a statewide coalition as one of 12 support teams across the US that are established as part of the NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities.

19 October 2020 NIH funds community engagement research efforts in areas hardest hit by COVID-19

The National Institutes of Health (NIH) recently announced a $12 million award for outreach and engagement efforts in ethnic and racial minority communities that are being disproportionately affected by the COVID-19 pandemic.

16 October 2020 Promising COVID-19 Research Awards Announced by American Lung Association, Clinical Trials Expanded with COVID-19 Research

As the COVID-19 pandemic reached the United States, the American Lung Association announced the COVID-19 Action Initiative, designed to accelerate the search for COVID-19 solutions.

16 October 2020 MSM Awarded $1 Million NIH Grant for COVID-19 Community Engagement Research and Health Communications

Morehouse School of Medicine received a $1 million award from the National Institutes of Health for COVID-19 pandemic outreach and engagement efforts in ethnic and racial minority communities.

16 October 2020 NIH Funds Community Engagement Research Efforts in Areas Hit Hardest by COVID-19

The National Institutes of Health today announced a $12 million award for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by the COVID-19 pandemic.

15 October 2020 Equipoise, Trust, and the Need for Cardiologists to Randomize Patients Into Anticoagulation Trials in the Time of COVID

In collaboration with the National Heart Lung and Blood Institute, Operation Warp Speed, the United States Food and Drug Administration, and as part of the Accelerating COVID19 Therapeutic Interventions and Vaccines(ACTIV) initiative...

12 October 2020 UMMC begins NIH study on COVID-19, community engagement

The University of Mississippi Medical Center received a $1 million grant for community outreach and engagement in minority communities heavily affected by COVID-19.

12 October 2020 CHER receives $1.2 million for health equity COVID-19 research

Researchers in Northern Arizona University’s Center for Health Equity Research (CHER) and the Southwest Health Equity Research Collaborative (SHERC) recently received four grants totaling more than $1 million from the National Institutes of Health (NIH) for projects related to the COVID-19 pandemic.

09 October 2020 Meharry Investigator to Lead NIH Community Research in TN for Vulnerable COVID-19 Populations

Nashville, Tenn.—Meharry Medical College Investigator Dr. Paul Juarez will lead the Community Engagement Alliance Against COVID-19 Disparities (CEAL) Team in Tennessee through a new research initiative funded by the National Institutes of Health (NIH).

08 October 2020 COVID-19 Should Force “Soul-Searching” Over Fragmented US Clinical Trials System, Woodcock Says

Among hundreds of trials underway on potential therapeutics, only about 6% of study arms are expected to yield actionable data because most are nonrandomized, underpowered or underenrolled, Operation Warp Speed’s Janet Woodcock says, renewing her pitch for adoption of master protocols and other approaches to streamline studies and improve efficiency.

07 October 2020 Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs

Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.

05 October 2020 Cary man shares his battle with COVID-19

I was at the point where I didn't think I was going to make it. I was really bad, suffering with the breathing and everything...

27 September 2020 Medicine faculty part of ACTIV-3 trial team lauded by NIH

A team of Duke Health clinicians that include faculty from the Department of Medicine are working diligently in a collaborative effort to enroll patients in a randomized, controlled trial, testing a novel antibody treatment for COVID-19.

25 September 2020 Duke Tests Novel COVID-19 Therapy, Is Lead Enroller in International Trial

The early stage of COVID-19 offers a critical window of opportunity to prevent the progression of the disease to the acute state, when patients require supportive care. By targeting the SARS-CoV-2 virus early on, a therapeutic can help to quickly eliminate the virus from the body while the patient’s symptoms are mild.

23 September 2020 COVID-19: An Update on the Federal Response

Chairman Alexander, Ranking Member Murray and distinguished members of Committee. It is an honor to appear before you today to discuss the Department of Health and Human Services’ ongoing response to the COVID-19 pandemic.

17 September 2020 HCS to lead state effort to raise awareness about COVID-19 in underserved communities

The University of North Texas Health Science Center at Fort Worth (HSC) will administer the Texas portion of a $12 million National Institutes of Health award for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by COVID-19.

16 September 2020 NIH funds community engagement research efforts in areas hardest hit by COVID-19

Outreach will focus on COVID-19 awareness and education research, especially among African Americans, Hispanics/Latinos, and American Indians.

15 September 2020 NIH Launches antithrombotics trials in COVID-19 patients

The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.

15 September 2020 Bridging the Gap at Warp Speed – Delivering Options for Preventing and Treating Covid-19

Operation Warp Speed (OWS), an effort of the U.S. Department of Health and Human Services and the Department of Defense in partnership with the private sector, is providing financial investment, scientific support, regulatory expertise, and logistic assistance to deliver vaccines, therapeutics, and diagnostics for SARS-CoV-2 to the American public as quickly as possible.

14 September 2020 NIH Launches Clinical Trials of Antithrombotic for COVID-19

Two of three planned adaptive phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19 have launched, according to an announcement by the National Institutes of Health (NIH).

14 September 2020 NIH ACTIV Initiative Launches Adaptive Clinical Trails of Blood-Clotting Treatments for COVID-19

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

14 September 2020 ACTIV-4 Antithrombotics Launched to Investigate Blood Thinners to Treat COVID-19 Patients

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

13 September 2020 NIH ACTIV Initiative Begins Adaptive Clinical Trials of Blood Clotting Treatments for COVID-19

Learn more about NIH’s ACTIV-4 clinical trials aimed at reducing blood clotting in patients with COVID-19 with NIH Director Dr. Francis Collins and NIH’s National Heart, Lung, and Blood Institute Director Dr. Gary Gibbons.

10 September 2020 NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

10 September 2020 Learner Team Plays Role in NIH COVID-19 Blood Clotting Treatment Trials

The University of Vermont (UVM) is participating in a major national research effort to evaluate the safety and effectiveness of varying types of blood thinners to treat adults diagnosed and hospitalized with COVID-19—the disease caused by SARS-CoV-2. The National Institutes of Health (NIH) announced the launch of two of three adaptive Phase 3 clinical trials September 10.

08 September 2020 NIH clinical trial explores use of convalescent plasma in at-risk outpatients with early COVID-19

Researchers supported by the National Institutes of Health have launched a key study to explore the safety and effectiveness of convalescent plasma in treating patients who have recently (within the last week) developed mild to moderate symptoms of COVID-19 disease. The study, which focuses on patients not yet hospitalized, comes on the heels of an announcement by the U.S. Food & Drug Administration (FDA) authorizing emergency use of convalescent plasma to help treat hospitalized patients with COVID-19.

01 September 2020 Event: Launching CONNECTS: Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies

Topic: Launching CONNECTS (Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies): A Partnership Between Research Triangle Institute, Vanderbilt University Medical Center, and the NHLBI. Date: Friday, September 11, 2020, 1:00-2:00 p.m. ET

13 August 2020 RTI researchers to help coordinate federal program seeking COVID-19 treatments

Federal health officials have tapped RTI International to join a collaboration tracking COVID-19’s ability to cause severe illness and the effectiveness of proposed treatments.

10 August 2020 Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

03 August 2020 4 former FDA commissioners: Blood plasma might be the covid-19 treatment we need

Blood plasma — also known as convalescent plasma — has been used as a therapy for infectious diseases for a century, including against the flu in 1918 as well as SARS, Ebola, meningitis and measles. While it doesn’t work for all infections, the idea is to use one person’s successful defense system of antibodies to bolster the immune response of a newly infected person.

30 July 2020 C3PO Clinical Trial

Michigan Medicine and three other medical centers receive $7 million for COVID-19 outpatient convalescent plasma therapy trial.

29 July 2020 COVID-19 trial to study convalescent plasma in outpatient setting

The Data Coordination Unit (DCU) in the Department of Public Health Sciences at the Medical University of South Carolina will take on the role of Data Coordinating Center for a $7 million national trial studying the role of convalescent plasma in mitigating the symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

28 July 2020 Pitt Collaborative to Study Outpatient Convalescent Plasma

A team of University of Pittsburgh, Michigan Medicine, Medical University of South Carolina and Stanford Medicine researchers recently were awarded funds from the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), totaling more than $7 million to collaboratively study the role of convalescent plasma in mitigating symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

27 July 2020 Phase 3 clinical trial of investigational vaccine for COVID-19 begins

A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun.

24 July 2020 COVID-19 Therapeutics Prioritized for Testing in Clinical Trials

The ACTIV public-private partnership has evaluated and prioritized therapeutic agents with potential application for COVID-19; and selected numerous NIH-supported networks to launch clinical trials to test prioritized therapeutic candidates.

20 July 2020 CHOC Hematologist Appointed to National COVID-19 Therapy Evaluation Oversight Committee

Dr. Diane Nugent has been named co-chair of the Steering Committee for the National Heart, Lung, and Blood Institute (NHLBI) Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies, or CONNECTS, which will coalesce projects into a national, coordinated effort. She will also serve on the Executive committee for CONNECTS to facilitate the rapid turnaround and implementation of these grants throughout the country.

15 July 2020 Launch Announcement: Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS)

The NHLBI’s Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS) is an important and innovative research effort. The goal of CONNECTS is to build on NHLBI’s existing clinical research networks across the nation and around the world to better understand the risk of severe illness from COVID-19 and to identify therapies that will slow or halt the disease progression and speed recovery.

13 July 2020 NHLBI's COVID-19 Research Strategy

Given the major impact of underlying heart, lung, and blood diseases and conditions on morbidity and mortality among patients with Coronavirus Disease 2019 (COVID-19), the NHLBI is pursuing a multi-pronged research strategy that leverages NHLBI-supported expertise, research, and infrastructure.